Immunic（10V）株式概要バイオテクノロジー企業であるImmunic, Inc.は、米国およびドイツにおいて、慢性炎症性疾患および自己免疫疾患の治療薬として選択的経口免疫療法のパイプラインを開発している。 詳細10V ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6リスク分析過去1年間で株主の希薄化は大幅に進んだ 収益が 100 万ドル未満 ( $0 )マイナスの株主資本 German市場と比較して、過去 3 か月間の株価の変動が非常に大きい+1 さらなるリスクすべてのリスクチェックを見る10V Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€7.76該当なし内在価値ディスカウントEst. Revenue$PastFuture-120m6k2016201920222025202620282031Revenue US$12.5Earnings US$2.1AdvancedSet Fair ValueView all narrativesUNCYFeaturedLooking to be second time lucky with a game-changing new productKey Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.View narrativeSTstuart_robertsCommunity ContributorUS$21.53FV • 64.4% 割安 内在価値ディスカウント5419.8%Revenue growth p.a.Set Fair Value6.2k1801283mo agoImmunic, Inc. 競合他社DarwinSymbol: MUN:7V0Market cap: €92.4mDextech MedicalSymbol: DB:LQ0Market cap: €185.8m2investSymbol: XTRA:2INVMarket cap: €62.9m2investSymbol: DB:2INVMarket cap: €48.3m価格と性能株価の高値、安値、推移の概要Immunic過去の株価現在の株価US$7.7652週高値US$12.6052週安値US$4.35ベータ1.371ヶ月の変化-21.46%3ヶ月変化49.81%1年変化-24.66%3年間の変化-48.20%5年間の変化-92.12%IPOからの変化-95.33%最新ニュースImmunic, Inc. Chief Medical Officer Changes, Effective April 24, 2026Apr 30Immunic, Inc. Appoints Jon Congleton to Its Board of Directors, Effective March 27, 2026Mar 31Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investorsFeb 18Immunic, Inc. Prioritizes Completion of the Ongoing Phase 3 Ensure Clinical Trials and Initiation of A Phase 3 Clinical Program in Primary Progressive Multiple SclerosisFeb 15Immunic, Inc. announced that it expects to receive $200 million in funding from a group of investorsFeb 14Immunic, Inc. Plans Transition of Daniel Vitt from CEOFeb 13+ 1 more update最新情報をもっと見るRecent updatesImmunic, Inc. Chief Medical Officer Changes, Effective April 24, 2026Apr 30Immunic, Inc. Appoints Jon Congleton to Its Board of Directors, Effective March 27, 2026Mar 31Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investorsFeb 18Immunic, Inc. Prioritizes Completion of the Ongoing Phase 3 Ensure Clinical Trials and Initiation of A Phase 3 Clinical Program in Primary Progressive Multiple SclerosisFeb 15Immunic, Inc. announced that it expects to receive $200 million in funding from a group of investorsFeb 14Immunic, Inc. Plans Transition of Daniel Vitt from CEOFeb 13+ 1 more updateImmunic to Present Additional Phase 2 Calliper Trial Data Foridofludimus Calcium At the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple SclerosisFeb 04Nasdaq Grants Immunic, Inc. an Additional 180-Day Grace Period to Regain Compliance with the Bid Price RuleJan 07Immunic, Inc.'s Subsidiary Gliomic Therapeutics Inc. Announces Executive Appointments, Effective January 1, 2026Jan 06Forecast to breakeven in 2028 Jan 01Immunic, Inc. Presents Key Vidofludimus Calcium Data At the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple SclerosisSep 25Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple SclerosisSep 09Immunic, Inc. Receives Notice of Nasdaq Non-Compliance with Minimum Bid Price RequirementJun 29Immunic, Inc. Reports New, Positive Long-Term Open-Label Extension Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple SclerosisJun 24Immunic, Inc. Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 Calliper Trial in Progressive MSJun 05Immunic, Inc. has announced a Derivatives Offering.May 29Immunic, Inc. Announces Positive Data from Phase 2 Calliper Trial of Nurr1 (Nurr1) Activator,Idofludimus Calcium (Imu-838) in Patients with Progressive Multiple SclerosisApr 30Immunic, Inc., Annual General Meeting, Jun 04, 2025Apr 24Immunic, Inc. has completed a Follow-on Equity Offering in the amount of $5.1 million.Apr 11Immunic, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.Apr 10Immunic, Inc.'s Oral IMU-856 Demonstrates Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical TestingFeb 21No longer forecast to breakeven Dec 30New minor risk - Market cap size Nov 16Independent Director recently bought €95k worth of stock Nov 15No longer forecast to breakeven Nov 11Immunic, Inc. to Report Q3, 2024 Results on Nov 07, 2024Oct 31Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple SclerosisOct 22Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID SyndromeSep 04New major risk - Financial position Aug 27New major risk - Share price stability Aug 26New minor risk - Profitability Aug 11No longer forecast to breakeven Aug 11New major risk - Financial position Aug 09Immunic, Inc. to Report Q2, 2024 Results on Aug 08, 2024Aug 01Immunic, Inc. Appoints Simona Skerjanec as Member of the BoardJul 24Immunic, Inc. Appoints Jason Tardio as Chief Operating Officer and PresidentJul 09New minor risk - Profitability May 10No longer forecast to breakeven May 10Immunic, Inc. to Report Q1, 2024 Results on May 08, 2024May 03Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationApr 30Immunic, Inc., Annual General Meeting, Jun 11, 2024Apr 24Immunic, Inc. to Report Fiscal Year 2023 Results on Feb 22, 2024Feb 16New major risk - Shareholder dilution Jan 25Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.Jan 05Forecast to breakeven in 2026 Dec 31New major risk - Financial position Nov 16Immunic, Inc. to Report Q3, 2023 Results on Nov 14, 2023Nov 08Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its SaltsNov 03Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023Oct 16Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple SclerosisOct 10Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple SclerosisAug 18New minor risk - Profitability Aug 06Immunic, Inc. to Report Q2, 2023 Results on Aug 03, 2023Jul 29Immunic, Inc. to Report Q1, 2023 Results on May 11, 2023May 10Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal DisordersMay 05High number of new directors May 01Immunic, Inc. to Report Q4, 2022 Results on Feb 23, 2023Feb 17Independent Director recently bought €96k worth of stock Dec 16Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective PotentialNov 18High number of new directors Nov 16Immunic, Inc. Provides Impairment Guidance for the Quarter Ending December 31, 2022Nov 04Immunic, Inc. to Report Q3, 2022 Results on Nov 03, 2022Oct 28Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo RateOct 21Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investorsOct 11Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human SubjectsSep 21Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel EpitheliumAug 18Immunic, Inc. to Report Q2, 2022 Results on Aug 04, 2022Jul 29Immunic, Inc. Announces Executive ChangesJul 07Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2000 Dynamic IndexJun 26+ 1 more updateImmunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational NeurologyJun 16Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative ColitisJun 03Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac DiseaseMay 06Immunic, Inc. to Report Q1, 2022 Results on May 10, 2022May 04High number of new directors Apr 27Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative ColitisFeb 19Immunic, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022Feb 18Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of Its Phase I Clinical Trial of IMU-935Dec 15Immunic, Inc. Announces Enrollment of the First Patient in Its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate CancerDec 10Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple SclerosisJul 02Immunic, Inc.(NasdaqGS:IMUX) dropped from Russell 2500 Growth IndexJun 28+ 2 more updatesImmunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing CholangitisFeb 19Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 TrialFeb 18New 90-day high: €17.20 Feb 11Iimmunic, Inc. Announces the Formation of a Scientific-Medical Advisory BoardNov 18Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19Nov 05Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19Sep 30Immunic, Inc. has completed a Follow-on Equity Offering in the amount of $90 million.Aug 06株主還元10VDE BiotechsDE 市場7D0%3.6%0.06%1Y-24.7%-11.2%1.0%株主還元を見る業界別リターン: 10V過去 1 年間で-11.2 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: 10Vは、過去 1 年間で1 % のリターンを上げたGerman市場を下回りました。価格変動Is 10V's price volatile compared to industry and market?10V volatility10V Average Weekly Movement21.6%Biotechs Industry Average Movement8.7%Market Average Movement6.0%10% most volatile stocks in DE Market12.3%10% least volatile stocks in DE Market2.6%安定した株価: 10Vの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 10Vの 週次ボラティリティ は、過去 1 年間で15%から22%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト201692Daniel Vittimux.comバイオテクノロジー企業であるImmunic, Inc.は、米国およびドイツにおいて、慢性炎症性疾患および自己免疫疾患の治療を目的とした選択的経口免疫療法のパイプラインを開発している。主な開発プログラムはIMU-838で、再発性・進行性多発性硬化症および中等度から重度の潰瘍性大腸炎患者を対象に臨床第3相および臨床第2相試験を実施中である。また、セリアック病、炎症性腸疾患、短腸症候群、下痢を伴う過敏性腸症候群、その他の腸管バリア機能疾患などの消化器疾患患者における腸管バリア機能の回復を適応症として、臨床第2相試験段階にあるIMU-856と、消化器疾患の治療を適応症として前臨床試験段階にあるIMU-381を開発している。Immunic, Inc.は2016年に設立され、ニューヨーク州ニューヨークに本社を置いている。もっと見るImmunic, Inc. 基礎のまとめImmunic の収益と売上を時価総額と比較するとどうか。10V 基礎統計学時価総額€111.99m収益（TTM）-€82.92m売上高(TTM)n/a0.0xP/Sレシオ-1.4xPER（株価収益率10V は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計10V 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$97.17m収益-US$97.17m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-7.15グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%10V の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 05:33終値2026/04/24 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Immunic, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関George FarmerBMO Capital Markets Equity ResearchWilliam WoodB. Riley Securities, Inc.Tyler BussianBrookline Capital Markets14 その他のアナリストを表示
UNCYFeaturedLooking to be second time lucky with a game-changing new productKey Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.View narrativeSTstuart_robertsCommunity ContributorUS$21.53FV • 64.4% 割安 内在価値ディスカウント5419.8%Revenue growth p.a.Set Fair Value6.2k1801283mo ago
Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investorsFeb 18
Immunic, Inc. Prioritizes Completion of the Ongoing Phase 3 Ensure Clinical Trials and Initiation of A Phase 3 Clinical Program in Primary Progressive Multiple SclerosisFeb 15
Immunic, Inc. announced that it expects to receive $200 million in funding from a group of investorsFeb 14
Immunic, Inc. announced that it has received $200.010837 million in funding from a group of investorsFeb 18
Immunic, Inc. Prioritizes Completion of the Ongoing Phase 3 Ensure Clinical Trials and Initiation of A Phase 3 Clinical Program in Primary Progressive Multiple SclerosisFeb 15
Immunic, Inc. announced that it expects to receive $200 million in funding from a group of investorsFeb 14
Immunic to Present Additional Phase 2 Calliper Trial Data Foridofludimus Calcium At the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple SclerosisFeb 04
Nasdaq Grants Immunic, Inc. an Additional 180-Day Grace Period to Regain Compliance with the Bid Price RuleJan 07
Immunic, Inc.'s Subsidiary Gliomic Therapeutics Inc. Announces Executive Appointments, Effective January 1, 2026Jan 06
Immunic, Inc. Presents Key Vidofludimus Calcium Data At the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple SclerosisSep 25
Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple SclerosisSep 09
Immunic, Inc. Reports New, Positive Long-Term Open-Label Extension Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple SclerosisJun 24
Immunic, Inc. Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 Calliper Trial in Progressive MSJun 05
Immunic, Inc. Announces Positive Data from Phase 2 Calliper Trial of Nurr1 (Nurr1) Activator,Idofludimus Calcium (Imu-838) in Patients with Progressive Multiple SclerosisApr 30
Immunic, Inc.'s Oral IMU-856 Demonstrates Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical TestingFeb 21
Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple SclerosisOct 22
Immunic, Inc. Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial ofidofludimus Calcium in Patients with Post COVID SyndromeSep 04
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationApr 30
Immunic, Inc. announced that it expects to receive $240 million in funding from BVF Partners L.P., Avidity Partners, LLC, Janus Henderson Investors, Soleus Capital, RTW Investments, LP, Adage Capital Management, L.P.Jan 05
Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its SaltsNov 03
Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023Oct 16
Immunic Reports Positive Interim Data from Phase 2 Calliper Trial of Vidofludimus Calcium in Progressive Multiple SclerosisOct 10
Immunic, Inc. Completes Enrollment of Its Phase 2 CallIPER Trial ofidofludimus Calcium in Progressive Multiple SclerosisAug 18
Immunic, Inc. Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal DisordersMay 05
Immunic, Inc Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective PotentialNov 18
Immunic, Inc. Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo RateOct 21
Immunic, Inc. announced that it expects to receive $59.949037 million in funding from a group of investorsOct 11
Immunic, Inc Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human SubjectsSep 21
Immunic, Inc. Receives Notice of Allowance for Composition-Of-Matter Patent in the United States for IMU-856, A Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel EpitheliumAug 18
Immunic, Inc. Announces Publication of Data From its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational NeurologyJun 16
Immunic, Inc. Reports Top-Line Data from Phase 2 Caldose-1 Trial of Vidofludimus Calcium in Patients with Moderate-To-Severe Ulcerative ColitisJun 03
Immunic, Inc. Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac DiseaseMay 06
Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative ColitisFeb 19
Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of Its Phase I Clinical Trial of IMU-935Dec 15
Immunic, Inc. Announces Enrollment of the First Patient in Its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate CancerDec 10
Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple SclerosisJul 02
Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing CholangitisFeb 19
Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 TrialFeb 18
Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19Nov 05
Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19Sep 30
